Shanghai ZJ Bio-Tech Co's revenue for the
three
months ended in Mar. 2026 was ¥25.4 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥118.1 Mil.
Shanghai ZJ Bio-Tech Co's Revenue per Share for the
three
months ended in Mar. 2026 was ¥0.15.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.69.
Warning Sign:
Shanghai ZJ Bio-Tech Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Shanghai ZJ Bio-Tech Co was -17.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -61.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -50.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 3.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Shanghai ZJ Bio-Tech Co's highest 3-Year average Revenue per Share Growth Rate was 120.60% per year. The lowest was -61.40% per year. And the median was 5.45% per year.
Shanghai ZJ Bio-Tech Co (SHSE:688317) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai ZJ Bio-Tech Co Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's Revenue distribution charts can be found below:
* The bar in red indicates where Shanghai ZJ Bio-Tech Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥118.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a Revenue of ¥118.1 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Shanghai ZJ Bio-Tech Co and its competitors.
Is Shanghai ZJ Bio-Tech Co's Revenue too high?
Shanghai ZJ Bio-Tech Co's current Revenue is ¥118.1 Mil. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's Revenue compare to ABT and SYK?
Shanghai ZJ Bio-Tech Co's Revenue of ¥118.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. Shanghai ZJ Bio-Tech Co's current Revenue is ¥118.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.89, compared to a current price of ¥15.97 — trading 61.5% above its estimated fair value. The current Revenue is ¥118.1 Mil. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current Revenue is ¥118.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued.
The current stock price of ¥15.97 is trading 61.5% above its estimated GF Value™ of ¥9.89.
GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688317:
Revenue: ¥118.1 Mil
GF Value™: ¥9.89 vs. price of ¥15.97 (61.5% above fair value)
No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
65GF Score
Get the complete analysis for SHSE:688317
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688317 has been successfully added to your 
